drugset / Trial / NCT02474368

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

NCT02474368 ↗

Phase 1 Active not recruiting 21 enrolled Dana-Farber Cancer Institute
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.

Timeline

Start
2015-11
Primary completion
2021-01
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified — Intravenous